{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-012028","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.138775+00:00","generated_at":"2026-05-16T10:24:03.184953+00:00","sec_items":["1.01","3.02","3.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcadia Biosciences raises $2.1M via exercise of options at reduced price; issues new options","bullets":["Gross proceeds of approx. $2.1M from exercise of 808,595 existing options at reduced price of $2.575/share.","Issued new unregistered options to purchase up to 1,617,190 shares at $2.325/share, expiring 30 months after resale registration effective date.","Existing options originally exercisable at $9.00/share; induced exercise by lowering price to $2.575.","Company to file resale registration statement for new option shares within 30 days of closing.","Net proceeds to be used for working capital and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-012028","json":"https://secwatch.observer/filing/0001193125-26-012028.json","markdown":"https://secwatch.observer/filing/0001193125-26-012028.md","text":"https://secwatch.observer/filing/0001193125-26-012028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/0001193125-26-012028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/rkda-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:24:03.184953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91140180398ca6ab67adb7cb44c59b1071b241b2","claim":"Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).","evidence_excerpt":"On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock (\"Common Stock\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/0001193125-26-012028-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Participating Holders"},{"label":"Value","value":"Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options"},{"label":"Effective","value":"2026-01-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}